Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs.
Artikel i vetenskaplig tidskrift, 2013

Background: It is currently unknown whether early immunomodulatory treatment in relapsing–remitting MS (RRMS) can delay the transition to secondary progression (SP). Objective: To compare the time interval from onset to SP in patients with RRMS between a contemporary cohort, treated with first generation disease modifying drugs (DMDs), and a historical control cohort. Methods: We included a cohort of contemporary RRMS patients treated with DMDs, obtained from the Swedish National MS Registry (disease onset between 1995–2004, n = 730) and a historical population-based incidence cohort (onset 1950–64, n = 186). We retrospectively analyzed the difference in time to SP, termed the “period effect” within a 12-year survival analysis, using Kaplan-Meier and Cox regression analysis. Results: We found that the “period” affected the entire severity spectrum. After adjusting for onset features, which were weaker in the contemporary material, as well as the therapy initiation time, the DMD-treated patients still exhibited a longer time to SP than the controls (hazard ratios: men, 0.32; women, 0.53). Conclusion: Our results showed there was a longer time to SP in the contemporary subjects given DMD. Our analyses suggested that this effect was not solely driven by the inclusion of benign cases, and it was at least partly due to the long-term immunomodulating therapy given

SPMS

RRMS

progression

multipel skleros

bromsmedicin

DMD

Författare

Helen Tedeholm

Göteborgs universitet

Jan Lycke

Göteborgs universitet

Bengt Skoog

Göteborgs universitet

Vera Lisovskaja

Göteborgs universitet

Chalmers, Matematiska vetenskaper, matematisk statistik

J Hillert

Karolinska universitetssjukhuset

C Dahle

Linköpings universitet

J Fagius

Akademiska Sjukhuset

S Fredrikson

Karolinska universitetssjukhuset

A-M Landtblom

Linköpings universitet

Clas Malmeström

Göteborgs universitet

C Martin

Danderyds sjukhus

F Piehl

Karolinska universitetssjukhuset

Björn Runmarker

Göteborgs universitet

L Stawiarz

Karolinska universitetssjukhuset

M Vrethem

Linköpings universitet

Olle Nerman

Chalmers, Matematiska vetenskaper, matematisk statistik

Göteborgs universitet

Oluf Andersen

Göteborgs universitet

Multiple Sclerosis

1352-4585 (ISSN) 1477-0970 (eISSN)

Vol. 19 6 765-774

Ämneskategorier

Klinisk medicin

DOI

10.1177/1352458512463764

PubMed

23124789

Mer information

Senast uppdaterat

2018-02-28